Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection of Pseudomonas aeruginosa
Pathogens · 2024
DOI: 10.3390/pathogens13020145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Zhiwen Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District,…. Hauptthemen laut MEDLINE: Biofilms, Pseudomonas aeruginosa, Prodigiosin, Pseudomonas Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, The Project of Chongqing Science and Technology Bureau, Project of Chongqing Science and Technology Bureau.
Abstract (Originalsprache)
Pseudomonas aeruginosa is known to generate bacterial biofilms that increase antibiotic resistance. With the increase of multi-drug resistance in recent years, the formulation of a new therapeutic strategy has seemed urgent. Preliminary findings show that Prodigiosin (PG), derived from chromium-resistant Serratia marcescens, exhibited efficient anti-biofilm activity against Staphylococcus aureus. However, its anti-biofilm activity against P. aeruginosa remains largely unexplored. The anti-biofilm activity of PG against three clinical single drug-resistant P. aeruginosa was evaluated using crystal violet staining, and the viability of biofilms and planktonic cells were also assessed. A model of chronic lung infection was constructed to test the in vivo antibiofilm activity of PG. The results showed that PG inhibited biofilm formation and effectively inhibited the production of pyocyanin and extracellular polysaccharides in vitro, as well as moderated the expression of interleukins (IL-1β, IL-6, IL-10) and tumor necrosis factor (TNF-α) in vivo, which might be attributed to the downregulation of biofilm-related genes such as algA, pelA, and pslM. These findings suggest that PG could be a potential treatment for drug-resistant P aeruginosa and chronic biofilm infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
Förderung
- National Natural Science Foundation of China
- The Project of Chongqing Science and Technology Bureau
- Project of Chongqing Science and Technology Bureau
Zitieren
APA
Ma, Z., Xiao, H., Li, H., Lu, X., Yan, J., Nie, H., & Yin, Q. (2024). Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection of Pseudomonas aeruginosa. Pathogens. https://doi.org/10.3390/pathogens13020145
Vancouver
Ma Z, Xiao H, Li H, Lu X, Yan J, Nie H, et al. Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection of Pseudomonas aeruginosa. Pathogens. 2024. doi:10.3390/pathogens13020145
BibTeX
@article{Ma2024,
author = {Ma, Zhiwen and Xiao, Hong and Li, Hailin and Lu, Xiaoling and Yan, Jing and Nie, Hao and Yin, Qi},
title = {Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection of Pseudomonas aeruginosa},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13020145}
}
EUVIMED